Allan Rettie
Titel
Geciteerd door
Geciteerd door
Jaar
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ...
New England Journal of Medicine 352 (22), 2285-2293, 2005
16562005
Estimation of the warfarin dose with clinical and pharmacogenetic data
International Warfarin Pharmacogenetics Consortium
New England Journal of Medicine 360 (8), 753-764, 2009
15392009
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
MK Higashi, DL Veenstra, LM Kondo, AK Wittkowsky, ...
Jama 287 (13), 1690-1698, 2002
12712002
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ...
Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008
8292008
The human intestinal cytochrome P450 “pie”
MF Paine, HL Hart, SS Ludington, RL Haining, AE Rettie, DC Zeldin
Drug Metabolism and Disposition 34 (5), 880-886, 2006
8142006
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions
AE Rettie, KR Korzekwa, KL Kunze, RF Lawrence, AC Eddy, T Aoyama, ...
Chemical research in toxicology 5 (1), 54-59, 1992
7061992
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
AE Rettie, LC Wienkers, FJ Gonzalez, WF Trager, KR Korzekwa
Pharmacogenetics and Genomics 4 (1), 39-42, 1994
5851994
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
KR Korzekwa, N Krishnamachary, M Shou, A Ogai, RA Parise, AE Rettie, ...
Biochemistry 37 (12), 4137-4147, 1998
5841998
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
GM Cooper, JA Johnson, TY Langaee, H Feng, IB Stanaway, UI Schwarz, ...
Blood 112 (4), 1022-1027, 2008
4552008
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
BF Gage, C Eby, PE Milligan, GA Banet, JR Duncan, HL McLeod
Thrombosis and haemostasis 91 (01), 87-94, 2004
4042004
CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant
MG McDonald, MJ Rieder, M Nakano, CK Hsia, AE Rettie
Molecular pharmacology 75 (6), 1337-1346, 2009
3642009
Genetic association between sensitivity to warfarin and expression of CYP2C9* 3
DJ Steward, RL Haining, KR Henne, G Davis, TH Rushmore, WF Trager, ...
Pharmacogenetics and Genomics 7 (5), 361-367, 1997
3531997
Identification and functional characterization of a new CYP2C9 variant (CYP2C9* 5) expressed among African Americans
LJ Dickmann, AE Rettie, MB Kneller, RB Kim, AJJ Wood, CM Stein, ...
Molecular pharmacology 60 (2), 382-387, 2001
3312001
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral …
RL Haining, AP Hunter, ME Veronese, WF Trager, AE Rettie
Archives of biochemistry and biophysics 333 (2), 447-458, 1996
3241996
Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics
AE Rettie, JP Jones
Annu. Rev. Pharmacol. Toxicol. 45, 477-494, 2005
2942005
Developmental expression of human hepatic CYP2C9 and CYP2C19
SB Koukouritaki, JR Manro, SA Marsh, JC Stevens, AE Rettie, ...
Journal of Pharmacology and Experimental Therapeutics 308 (3), 965-974, 2004
2892004
Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid
AE Rettie, AW Rettenmeier, WN Howald, TA Baillie
Science 235 (4791), 890-893, 1987
2851987
Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
DL Veenstra, JHS You, MJ Rieder, FM Farin, HW Wilkerson, DK Blough, ...
Pharmacogenetics and genomics 15 (10), 687-691, 2005
2712005
Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6
W Chen, LL Koenigs, SJ Thompson, RM Peter, AE Rettie, WF Trager, ...
Chemical research in toxicology 11 (4), 295-301, 1998
2491998
Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3
DH Lang, CK Yeung, RM Peter, C Ibarra, R Gasser, K Itagaki, RM Philpot, ...
Biochemical pharmacology 56 (8), 1005-1012, 1998
2471998
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20